Back to Search Start Over

Management of Myocardial Revascularization in Patients With Stable Coronary Artery Disease Undergoing Transcatheter Aortic Valve Implantation

Authors :
Costa, Giuliano
Pilgrim, Thomas
Amat Santos, Ignacio J
De Backer, Ole
Kim, Won-Keun
Barbosa Ribeiro, Henrique
Saia, Francesco
Bunc, Matjaz
Tchetche, Didier
Garot, Philippe
Ribichini, Flavio Luciano
Mylotte, Dzxcfewarren
Burzotta, Francesco
Watanabe, Yusuke
De Marco, Federico
Tesorio, Tullio
Rheude, Tobias
Tocci, Marco
Franzone, Anna
Valvo, Roberto
Savontaus, Mikko
Wienemann, Hendrik
Porto, Italo
Gandolfo, Caterina
Iadanza, Alessandro
Bortone, Alessandro Santo
Mach, Markus
Latib, Azeem
Biasco, Luigi
Taramasso, Maurizio
Zimarino, Marco
Tomii, Daijiro
Nuyens, Philippe
Sondergaard, Lars
Camara, Sergio F
Palmerini, Tullio
Orzalkiewicz, Mateusz
Steblovnik, Klemen
Degrelle, Bastien
Gautier, Alexandre
Del Sole, Paolo Alberto
Mainardi, Andrea
Pighi, Michele
Lunardi, Mattia
Kawashima, Hideyuki
Criscione, Enrico
Cesario, Vincenzo
Biancari, Fausto
Zanin, Federico
Joner, Michael
Esposito, Giovanni
Adam, Matti
Grube, Eberhard
Baldus, Stephan
De Marzo, Vincenzo
Piredda, Elisa
Cannata, Stefano
Iacovelli, Fortunato
Andreas, Martin
Frittitta, Valentina
Dipietro, Elena
Reddavid, Claudia
Strazzieri, Orazio
Motta, Silvia
Angellotti, Domenico
Sgroi, Carmelo
Kargoli, Faraj
Tamburino, Corrado
Barbanti, Marco
Publication Year :
2022
Publisher :
LIPPINCOTT WILLIAMS & WILKINS, 2022.

Abstract

Background: The best management of stable coronary artery disease (CAD) in patients undergoing transcatheter aortic valve implantation (TAVI) is still unclear due to the marked inconsistency of the available evidence. Methods: The REVASC-TAVI registry (Management of Myocardial Revascularization in Patients Undergoing Transcatheter Aortic Valve Implantation With Coronary Artery Disease) collected data from 30 centers worldwide on patients undergoing TAVI who had significant, stable CAD at preprocedural work-up. For the purposes of this analysis, patients with either complete or incomplete myocardial revascularization were compared in a propensity score matched analysis, to take into account of baseline confounders. The primary and co-primary outcomes were all-cause death and the composite of all-cause death, stroke, myocardial infarction, and rehospitalization for heart failure, respectively, at 2 years. Results: Among 2407 patients enrolled, 675 pairs of patients achieving complete or incomplete myocardial revascularization were matched. The primary (21.6% versus 18.2%, hazard ratio‚ 0.88 [95% CI, 0.66–1.18]; P =0.38) and co-primary composite (29.0% versus 27.1%, hazard ratio‚ 0.97 [95% CI, 0.76–1.24]; P =0.83) outcome did not differ between patients achieving complete or incomplete myocardial revascularization, respectively. These results were consistent across different prespecified subgroups of patients (< or >75 years of age, Society of Thoracic Surgeons score > or or P values for interaction >0.10). Conclusions: The present analysis of the REVASC-TAVI registry showed that, among TAVI patients with significant stable CAD found during the TAVI work-up, completeness of myocardial revascularization achieved either staged or concomitantly with TAVI was similar to a strategy of incomplete revascularization in reducing the risk of all cause death, as well as the risk of death, stroke, myocardial infarction, and rehospitalization for heart failure at 2 years, regardless of the clinical and anatomical situations.

Details

Language :
English
Database :
OpenAIRE
Accession number :
edsair.doi.dedup.....804d0c3d10d53fa119c51b075b3b6bad